"The Pros and Cons of Testing PSA Levels for Prostate Cancer"
While 64 percent of men develop hidden prostate cancers
by their 60s,
the lifetime risk of being diagnosed with prostate cancer
is only about 11 percent,
and the risk of dying from prostate cancer, 2.5 percent,
at the average age of 80.
So most men develop prostate cancer
but they die with their tumors
rather than from their tumors.
Most men with prostate cancer live their whole lives
never knowing they even had it.
That's one of the problems screening for it.
Many prostate cancers that are detected
may never have led to harm
even if they'd gone undiscovered.
Nonetheless, not all men are so lucky.
About 30,000 Americans die each year from prostate cancer.
So, should you get a PSA prostate screening test or not?
PSA stands for prostate specific antigen,
an enzyme secreted by cells of the prostate
to liquefy semen and cervical mucus
to facilitate fertilization.
Elevated levels in the blood can be a sign of prostate cancer,
which led to FDA approval as a screening test
for the early detection of prostate cancer in the 1990s.
If it comes back high, the test is usually repeated.
If it's still high,
the next step is typically
an ultrasound-guided biopsy of the prostate
through the rectum.
If there's cancer,
then options include surgery, radiation, and chemotherapy,
or a delayal of treatment.
However the USPSTF,
the US Preventive Services Task Force,
the main independent scientific panel
that sets evidence-based clinical prevention guidelines,
recommended against routine PSA screening,
as does the American College of Preventive Medicine,
the American Academy of Family Physicians,
and the vast majority,
85 percent of professional medical societies
in developed countries around the world, opposed.
In 2018, though,
the USPSTF shifted from a summary judgement against
to, quote, "the decision about whether to be screened
for prostate cancer should be an individual one," unquote,
which is more in line with the "shared decision making" stance
of the American Urological Association,
the American College of Physicians,
and the American Cancer Society.
In other words,
men should be informed about the risks and benefits
and decide for themselves.
However, men who are on the fence
and don't express a clear preference
in favor of screening should not be screened,
according to the latest USPSTF recommendations.
More recently, an international panel of experts concluded
that clinicians need not feel obligated
to systematically bring it up,
judging that most men would decide to decline PSA testing,
given the clear harms and small and uncertain benefits.
That, however, is up to you.
I personally declined, but let's run the numbers.
Similar to the 92 percent of women who didn't know
or overestimated the mortality reduction from mammograms
by tenfold or more,
89 percent of men vastly overestimated the benefits
of prostate cancer screening
or simply had no idea.
Most thought 50 prostate cancer deaths could be prevented
out of a thousand men regularly screened,
when in reality, it's more like one.
But doesn't even a 1-in-1,000 chance of not dying from cancer
make a few blood tests worth it?
The downsides are more than inconvenience, though.
About one in seven men who undergo PSA screening
will test positive,
yet in two-thirds of the cases,
the biopsy results will be normal.
So out of the thousand men regularly screened,
about 150 will have a false alarm
and be biopsied unnecessarily,
which can cause minor complications
like pain and bloody ejaculate,
or in approximately 1 percent of cases,
more serious complications,
like blood-borne infections that require hospitalization.
The greatest harm, though, is overdiagnosis.
Unnecessary biopsies are bad enough,
but nothing, compared to unnecessary cancer treatment.
Large-scale randomized trials suggest that
20 to 50 percent of men diagnosed with prostate cancer
would have never become symptomatic in their lifetime.
They never would have been any wiser
had they not been screened,
but now they may be needlessly heading to the operating table.
About 3 in 1,000 men die during or soon after
radical prostatectomy.
That may help explain why there appears to be
no overall mortality benefit to prostate cancer screening.
For every life that is saved,
another may be extinguished for a cancer
they never would have even known about.
Another 50 in 1,000 men
end up with serious surgical complications.
Even if the surgery goes smoothly,
about one in five men develop long-term urinary incontinence
requiring the use of pads,
and most men-- two out of three--
will experience long-term erectile dysfunction.
Most men who receive radiation therapy
also experience long-term sexual erectile dysfunction
and up to one in six experience long-term bowel issues
such as fecal incontinence.
If this was saving your life, it would be worth it,
but over 16 years,
rather than being saved from a prostate cancer death
by screening,
it may be 25 times more likely that you were instead
overdiagnosed with a cancer that wouldn't have bothered you.
Yet you come away after treatment
thinking the PSA test saved your life.
It's like with the mammograms.
The people who are harmed the most--
unnecessary cancer treatment--
feel as though they've been helped the most.